An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection

Onychomycosis Clinical Trial

Official title:

An Open-label Cosmetic Study to Evaluate the Effectiveness of CGB-400 Topical Gel for Improving Appearance of Toenails Affected by Fungal Infection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05202366
• Other study ID #: CGB-405
• Status: Recruiting
• Start date: February 8, 2022
• Est. completion date: September 15, 2022

Study information

• Verified date: April 2022
• Source: CAGE Bio Inc.
• Contact: Abhirup Mandal, PhD
• Phone: 8167181914
• Email: amandal[@]cagebio.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of the current study is to evaluate the ability of CGB-400, a proprietary eutectic mixture of GRAS compounds, to clear the toenail fungal growth and improve the appearance of the fungus affected area(s).

This is an open-label, single group POC study evaluating the effectiveness of CGB-400 Topical Gel for toenail fungal growth clearing. The study consists of a 12-week period with 5 clinic visits at the following timepoints: Baseline (Day 0), and Weeks 2, 6, and 12 and post-application follow-up at Week 24. The applications could be extended for an additional 12 weeks based on PI's observations.

Approximately 15 subjects will be enrolled and subjected to application of CGB-400 Topical Gel. Subjects must be at least 18 years of age and will be selected by the concerned PI.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: September 15, 2022
• Est. primary completion date: August 8, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria:

1. Male or female =18 (and =99) at the time of Informed Consent.

2. Nail fungal infection of at least one great toe [per visual assessment by the clinical investigator]

3. Subjects who have target toenail showing 20-65% involvement as judged by the clinical investigator.

4. Subject must be physically able to reach toes to clean them and apply product.

5. Subject is willing to discontinue use of other nail fungus treatment products and nail cosmetic products for duration of this study.

6. Subject is willing and available to return for study follow up.

7. Signed written informed consent form (ICF) prior to any trial related activity (subjects must have the mental, literate, and legal ability to give a written informed consent, which must comply with the ICH GCP guidelines and local requirements.

8. Agree to take and share pictures of the treated toenails on a periodic basis during the study and follow-up period.

Exclusion Criteria:

1. Female subjects that are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control.

2. Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Product (i.e., essential oils, fragrance, choline, phosphatidylcholine, propylene glycol, limonene, cellulose).

3. Nails with clinical evidence of no or low distal growth.

4. History or presence of another skin/nail condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.).

5. Basal cell carcinoma within 6 months of Visit 1.

6. Uncontrolled systemic disease.

7. Foreseen unprotected and intense/excessive UV exposure during the course of the study.

8. Use of prohibited concomitant medications/procedures, as specified below in Table 2, during the study or within the defined washout periods.

9. Scheduled or planned surgical procedures during the course of the study.

10. Unable or unwilling to comply with any of the study requirements.

11. Medical or psychiatric conditions, or a personal situation, that may increase the risk associated with study participation or may interfere with interpretation of study results or subject compliance and, in the opinion of the PI, makes the subject inappropriate for study entry.

12. Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.

13. Exposure to any other investigational drug/device within 30 days prior to study entry.

Related Conditions & MeSH terms

• Communicable Diseases
• Fungal Infection
• Infections
• Mycoses
• Onychomycosis
• Tinea Unguium

Intervention

Drug:
• CGB-400 Topical Gel
CGB-400 Gel contains two main ingredients: geranic acid and choline. Geranic acid, a naturally occurring essential oil/terpenoid, is a key ingredient in lemon grass and is also found in other natural materials such as cardamom. The other main ingredient in CAGE is choline, which is an essential dietary component and found in foods as free choline and as several esterified forms such as phosphocholine and phosphatidylcholine.

Locations

Country	Name	City	State
United States	John Peter Smith Hospital	Fort Worth	Texas

Sponsors (2)

Lead Sponsor	Collaborator
CAGE Bio Inc.	John Peter Smith Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Subject Global Assessment	The Subject Global Assessment will be collected in the form "subject questionnaire"; SUBJECT QUESTIONNAIRE: The Investigator (or designate) will ask the following questions at the Baseline visit and subject's answers will be recorded: How frequently do you typically experience fungal growth each month?; How do you rate your fungal growth today relative to other times?; Are you aware of specific triggers that aggravate fungal growth?; How do you deal with or treat fungal growth?; What other products have you tried in the past for managing/treating fungal growth?; Are there any other aspects of fungal growth or experience that we should know about?	24 weeks
Primary	Investigator Global Assessment (IGA) of affected toenails	Clear 0% nail involvement; Almost clear 0%-=10% nail involvement; Mild 10%-<25% nail involvement; Moderate 25%-=50% nail involvement; Severe >50%-=75% nail involvement	24 weeks
Secondary	Percent clear area on affected toenail/region (s)	*Clear nail is defined as area from proximal nail fold till most proximal area of abnormality with evidence of persistent clear growth.; Clearance must be progressively observed over two time points.	24 weeks
Secondary	Visual inspection (pictures to be collected)	Visual inspection for application site reactions: performed at each visit along with images taken by subjects and at the time of clinic visit	24 weeks